ATOMIC (Academic Thoracic Oncology Medical Investigators Consortium), met at the IASLC 2023 Targeted Therapies of Lung Cancer symposium in February in Santa Monica. ATOMIC is an innovative research model that has brought together an expert team of institutions and investigators to design and rapidly complete clinical trials in thoracic and lung cancer with the ultimate goal of identifying new drugs to treat this disease.
Leading the group is D. Ross Camidge, MD, PhD. Dr. Camidge is Professor of Medicine/Oncology and holds the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado. He was educated at Cambridge University (MRC Laboratory of Molecular Biology), Cambridge, UK – 1992; and Oxford University Medical School, Oxford, UK – 1995. He joined the University of Colorado as a visiting professor in November of 2005 and was recruited as full-time faculty in October of 2007. He is dual trained in both medical oncology and clinical pharmacology.
“Meeting in-person again helps us connect and focus on the best pathway to continue to grow the consortium’s future. It’s also a fun way to continue to extend the cross-institutional mentorship that is one of the founding principles of ATOMIC.”
—D. Ross Camidge, M.D., PhD.
ATOMIC is a proud member of Criterium’s established consortia: Academic Breast Cancer Consortium (ABRCC), Academic Urology Research Investigators Consortium (AURIC), Academic Myeloma Consortium (AMyC)